Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 41, Issue 5, 2006, Pages 590-597

  Mulligan, Kathleen ^a   Parker, Robert A ^b   Komarow, Lauren ^b   Grinspoon, Steven K ^b   Tebas, Pablo ^c   Robbins, Gregory K ^b   Roubenoff, Ronenn ^d   Dubé, Michael P ^e,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d TUFTS UNIVERSITY   (United States)

^e INDIANA UNIVERSITY   (United States)

^f WISHARD MEMORIAL HOSPITAL   (United States)

Author keywords

Anthropometry; Antiretroviral therapy; DEXA; Fat distribution; HIV; Lipodystrophy

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY FAT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBCUTANEOUS FAT; TISSUE DISTRIBUTION; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT GAIN;

ADIPOSE TISSUE; ADULT; ANTI-HIV AGENTS; BODY SIZE; BODY WEIGHT; DENSITOMETRY, X-RAY; FEMALE; HIV INFECTIONS; HUMANS; MALE; REGRESSION ANALYSIS;

EID: 33646811534     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000214811.72916.67     Document Type: Article

References (25)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance due to HIV protease inhibitors. AIDS. 1998;12:F51-F58.
2. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13(13):1659-1667.
3. Engelson ES, Kotler DP, Tan YX, et al. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr. 1999;69:1162-1169.
4. Lo JC, Mulligan K, Tai VW, et al. "Buffalo hump" in men with HIV-1 infection. Lancet. 1998;351:861-870.
5. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 1998;351:871-875.
6. Miller KK, Daly PA, Sentochnik D, et al. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis. 1998;27:68-72.
7. Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immun Defic Syndr. Oct 1 2005;40(2):121-131.
8. Mulligan K, Tai VW, Algren H, et al. Altered fat distribution in distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy. J Acquir Immun Defic Syndr. 2001;26:443-448.
9. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS. 2000;14(1):37-49.
10. Dubé MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005;19:1807-1818.
11. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191-201.
12. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS. 2002;16(18):2447-2454.
13. Shlay JC, Visnegarwala F, Bartsch G, et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immun Defic Syndr. 2005;38:147-155.
14. Terry RB, Page WF, Haskell WL. Waist/hip ratio, body mass index and premature cardiovascular disease mortality in US Army veterans during a twenty-three year follow-up study. Int J Obes Relat Metab Disord. 1992;16:417-423.
15. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
16. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349(24):2293-2303.
17. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349(24):2304-2315.
18. Centers for Disease Control. The Third national Health and Nutrition Examination Survey (NHANES III 1988-1994) Reference Manuals and Reports: Body Measurements (Anthropometry). Rockville, MD, 1988.
19. Fieller CE, Hartley HO, Pearson ES. Tests for rank correlation coefficients I. Biometrika. 1957;44:470-481.
20. Mallon PW, Miller J, Cooper DA, et al. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17(7):971-979.
21. Vigouroux C, Maachi M, Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS. 2003;17(10):1503-1511.
22. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr. 2004;79:379-384.
23. Pouliot MC, Despres JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73:460-468.
24. Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immun Defic Syndr. 2005;39:44-54.
25. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;288(2):207-215.